Aktuellt
SENASTE
Redeye maintains our positive take on C21 in IPF following last weeks Key Opinion Leader Seminar hosted by Vicore Pharma. Furthermore, we comment on the external Covid-19 news that Merck’s antiviral candidate Molnupiravir showed promising data in a phase III study in mild to moderate Covid-19.
LÄS MER
